Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy
Prostate cancer (PCa) is one of the most prevalent cancer diagnoses among men in the United States and in several other developed countries. The prostate specific membrane antigen (PSMA) has been recognized as a promising molecular target in PCa, which has led to the development of specific radionuc...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/18/4537 |
| _version_ | 1797580872473378816 |
|---|---|
| author | Mohammed Abusalem Lucia Martiniova Sarita Soebianto Louis DePalatis Gregory Ravizzini |
| author_facet | Mohammed Abusalem Lucia Martiniova Sarita Soebianto Louis DePalatis Gregory Ravizzini |
| author_sort | Mohammed Abusalem |
| collection | DOAJ |
| description | Prostate cancer (PCa) is one of the most prevalent cancer diagnoses among men in the United States and in several other developed countries. The prostate specific membrane antigen (PSMA) has been recognized as a promising molecular target in PCa, which has led to the development of specific radionuclide-based tracers for imaging and radiopharmaceuticals for PSMA targeted therapy. These compounds range from small molecule ligands to monoclonal antibodies (mAbs). Monoclonal antibodies play a crucial role in targeting cancer cell-specific antigens with a high degree of specificity while minimizing side effects to normal cells. The same mAb can often be labeled in different ways, such as with radionuclides suitable for imaging with Positron Emission Tomography (β+ positrons), Gamma Camera Scintigraphy (γ photons), or radiotherapy (β− electrons, α-emitters, or Auger electrons). Accordingly, the use of radionuclide-based PSMA-targeting compounds in molecular imaging and therapeutic applications has significantly grown in recent years. In this article, we will highlight the latest developments and prospects of radiolabeled mAbs that target PSMA for the detection and treatment of prostate cancer. |
| first_indexed | 2024-03-10T22:57:13Z |
| format | Article |
| id | doaj.art-5442c8a0d0d64380b590dacf2dc0deb4 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T22:57:13Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5442c8a0d0d64380b590dacf2dc0deb42023-11-19T09:55:11ZengMDPI AGCancers2072-66942023-09-011518453710.3390/cancers15184537Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and TherapyMohammed Abusalem0Lucia Martiniova1Sarita Soebianto2Louis DePalatis3Gregory Ravizzini4Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USABioDevelopment Solutions, LLC, 226 Becker Circle, Johnstown, CO 80534, USADepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAProstate cancer (PCa) is one of the most prevalent cancer diagnoses among men in the United States and in several other developed countries. The prostate specific membrane antigen (PSMA) has been recognized as a promising molecular target in PCa, which has led to the development of specific radionuclide-based tracers for imaging and radiopharmaceuticals for PSMA targeted therapy. These compounds range from small molecule ligands to monoclonal antibodies (mAbs). Monoclonal antibodies play a crucial role in targeting cancer cell-specific antigens with a high degree of specificity while minimizing side effects to normal cells. The same mAb can often be labeled in different ways, such as with radionuclides suitable for imaging with Positron Emission Tomography (β+ positrons), Gamma Camera Scintigraphy (γ photons), or radiotherapy (β− electrons, α-emitters, or Auger electrons). Accordingly, the use of radionuclide-based PSMA-targeting compounds in molecular imaging and therapeutic applications has significantly grown in recent years. In this article, we will highlight the latest developments and prospects of radiolabeled mAbs that target PSMA for the detection and treatment of prostate cancer.https://www.mdpi.com/2072-6694/15/18/4537PSMAradiolabeled mAbsprostate cancerimagingtargeted radionuclide therapy |
| spellingShingle | Mohammed Abusalem Lucia Martiniova Sarita Soebianto Louis DePalatis Gregory Ravizzini Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy Cancers PSMA radiolabeled mAbs prostate cancer imaging targeted radionuclide therapy |
| title | Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy |
| title_full | Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy |
| title_fullStr | Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy |
| title_full_unstemmed | Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy |
| title_short | Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy |
| title_sort | current status of radiolabeled monoclonal antibodies targeting psma for imaging and therapy |
| topic | PSMA radiolabeled mAbs prostate cancer imaging targeted radionuclide therapy |
| url | https://www.mdpi.com/2072-6694/15/18/4537 |
| work_keys_str_mv | AT mohammedabusalem currentstatusofradiolabeledmonoclonalantibodiestargetingpsmaforimagingandtherapy AT luciamartiniova currentstatusofradiolabeledmonoclonalantibodiestargetingpsmaforimagingandtherapy AT saritasoebianto currentstatusofradiolabeledmonoclonalantibodiestargetingpsmaforimagingandtherapy AT louisdepalatis currentstatusofradiolabeledmonoclonalantibodiestargetingpsmaforimagingandtherapy AT gregoryravizzini currentstatusofradiolabeledmonoclonalantibodiestargetingpsmaforimagingandtherapy |